A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
ConditionDLBCL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
Eligibility criteria
Qualifiers
Having sufficient understanding of this study and being willing to sign the informed consent form (ICF);
Age above 18 years old (including 18 years old)，regardless of gender;
Treatment-naive, histologically confirmed DLBCL, at least one tumor lesion that could be measured accurately at baseline according to RECIST1.1 criteria;
IPI score 0-2;
Disqualifiers
The subject is participating in other interventional clinical studies;
The subject has previous or concurrent other malignancies;
Lymphoma bone marrow invasion;
The presence of symptomatic brain metastases requiring immediate radiotherapy or steroid therapy;
Trial design
Treatments tested in this trial
- Trilaciclib+R-CHOP
Treatment groups
38 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov